Investors May Worry About Pro-Dex's (NASDAQ:PDEX) Capital Returns
Pro-Dex's ROCE Performance: Pro-Dex has a return on capital employed (ROCE) of 21%, which is significantly higher than the industry average of 11%, indicating strong profitability relative to its capital employed.
Trends in Capital and Revenue: Although Pro-Dex's ROCE has decreased from 27% over the past five years, both revenue and capital employed have increased, suggesting the company is investing in growth.
Investment Potential: The stock has delivered a 1.8% gain to shareholders over the last five years, prompting a recommendation for further investigation into its investment potential.
Risks and Warnings: Despite its strong returns, Pro-Dex has been flagged with two warning signs in the investment analysis, indicating potential risks for investors.
Trade with 70% Backtested Accuracy
Analyst Views on PDEX
About PDEX
About the author

Pro-Dex Reports Q2 Earnings with Revenue of $1.9M
- Earnings Highlights: Pro-Dex reported a Q2 GAAP EPS of $0.66, with revenue at $1.9 million, indicating stable performance in the niche surgical tools market and reflecting its competitive position in this segment.
- Market Valuation: Pro-Dex is viewed as an attractive microcap despite customer risks, suggesting that its valuation may appeal to investors seeking undervalued opportunities in the market.
- Rating Analysis: Seeking Alpha's quantitative rating on Pro-Dex indicates a cautiously optimistic outlook from the market, highlighting investor interest in its potential growth, particularly in the surgical tools sector.
- Financial Transparency: The disclosure of financial information enhances investor confidence, as stable profitability, despite relatively low revenue, may lay the groundwork for future growth.

Pro-Dex (PDEX) Extends Major Customer Contract by Three Years, Anticipates Revenue Growth
- Contract Extension: Pro-Dex executed a contract amendment on December 17, 2025, with its largest customer, extending the agreement through December 31, 2028, which includes minimum purchase volumes, thereby positioning the company for sustained revenue growth over the next three years.
- Sales Performance Surge: For the fiscal first quarter ending September 30, 2025, Pro-Dex reported net sales of $18.5 million, a 24% increase from $14.9 million year-over-year, primarily driven by resumed shipments to its largest customer, indicating robust market demand.
- Net Income Growth: The company's net income rose to $4.7 million, or $1.40 per diluted share, compared to $2.5 million, or $0.75 per diluted share a year earlier, reflecting the successful launch and sales of its next-generation surgical handpiece.
- Optimistic Market Outlook: Pro-Dex anticipates that the extended contract will provide stability as it continues to innovate in surgical instrumentation and expand consulting services, further solidifying its position in the medical device market.






